Product Description
Mechanisms of Action: IL4 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Zhixiang (Shanghai) Pharmaceutical Technology Co., Ltd./Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 16
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Chronic Rhinosinusitis with Nasal Polyps|Chronic Spontaneous Urticaria|Dermatitis, Atopic|Nasal Polyposis|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal|Sinusitis
Phase 2: Asthma
Phase 1: Asthma, Allergic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07154342 |
GR1802-014 | P3 |
Recruiting |
Rhinitis, Allergic, Seasonal |
2026-04-30 |
2025-09-05 |
||
NCT06516302 |
GR1802-007 | P3 |
Active, not recruiting |
Chronic Rhinosinusitis with Nasal Polyps |
2026-03-01 |
15% |
2026-03-04 |
Primary Endpoints |
CTR20221056 |
CTR20221056 | P2 |
Completed |
Asthma |
2025-12-01 |
2026-02-15 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT06315426 |
GR1802-011 | P2 |
Active, not recruiting |
Rhinitis, Allergic |
2025-05-01 |
2025-04-26 |
Primary Endpoints |
|
CTR20242794 |
CTR20242794 | P3 |
Completed |
Sinusitis|Nasal Polyposis |
2026-07-27 |
2026-10-13 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252995 |
CTR20252995 | P1 |
Completed |
Dermatitis, Atopic|Asthma, Allergic|Sinusitis|Rhinitis, Allergic, Seasonal|Nasal Polyposis|Chronic Spontaneous Urticaria |
2026-01-30 |
2026-02-10 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20223248 |
CTR20223248 | P2 |
Completed |
Nasal Polyposis|Sinusitis |
2024-10-21 |
2025-06-01 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233857 |
CTR20233857 | P3 |
Completed |
Dermatitis, Atopic |
2025-12-15 |
2025-12-21 |
||
NCT07199257 |
GR1802-015 | P3 |
Not yet recruiting |
Rhinitis, Allergic, Seasonal |
2027-05-15 |
2025-10-01 |
Primary Endpoints|Treatments |
|
CTR20253037 |
CTR20253037 | P3 |
Completed |
Rhinitis, Allergic |
2026-01-30 |
2026-02-15 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20250174 |
CTR20250174 | P3 |
Active, not recruiting |
Chronic Spontaneous Urticaria |
None |
2026-07-26 |
Patient Enrollment|Treatments|Trial Status |
|
CTR20251242 |
CTR20251242 | P1 |
Completed |
Sinusitis|Nasal Polyposis |
2025-10-11 |
2026-02-10 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20244828 |
CTR20244828 | P1 |
Recruiting |
Dermatitis, Atopic |
None |
2025-05-11 |
Patient Enrollment|Start Date|Treatments|Trial Status |
|
CTR20240601 |
CTR20240601 | P2 |
Completed |
Rhinitis, Allergic, Seasonal |
2025-09-30 |
2026-02-10 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232213 |
CTR20232213 | P2 |
Completed |
Nasal Polyposis|Sinusitis |
2025-04-17 |
2025-05-17 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230559 |
CTR20230559 | P2 |
Completed |
Chronic Spontaneous Urticaria |
2024-10-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|